Latest results FY2025 · Prices updated Oct 30, 2026
HQ: Kawasaki, KanagawaFounded 2006157 employeesWebsite
A global leader in macrocyclic peptide drug discovery using its proprietary PDPS platform. It collaborates extensively with major global pharmaceutical companies to develop next-generation therapeutics.
Business segments (share of revenue)
Latest results
FY2025
vs. same period a year earlier
Company forecastFY2026
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Radiopharmaceutical Business Operations | 85% | ¥15.7B | ¥435M | 2.8% |
| Drug Discovery and R&D | 15% | ¥2.8B | ¥-5.4B | -191.8% |
Close (Oct 30, 2026)
¥1,117-28.4% (1Y)
Peptide Dream -28.4% over 1Y, 43.2pt below the industry average (23 companies, +14.8%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2025FY | ¥18.5B | ¥-5.0B | ¥-3.7B | ¥77.0B | -60.3% |
| 2024FY | ¥46.7B | ¥21.1B | ¥15.0B | — | +62.6% |
| 2023FY | ¥28.7B | ¥6.8B | ¥3.0B | — | +6.9% |
| 2022FY | ¥26.9B | ¥9.0B | ¥7.6B | — | +186.7% |
| 2021FY | ¥9.4B | ¥4.4B | ¥3.6B | — | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
